Alpha Cognition (OTC:ACOGF) and ZIVO Bioscience (NASDAQ:ZIVO) Head to Head Review

Profitability

This table compares Alpha Cognition and ZIVO Bioscience’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Alpha Cognition	N/A	N/A	-522.43%
ZIVO Bioscience	N/A	N/A	-2,240.92%

Institutional and Insider Ownership

12.8% of ZIVO Bioscience shares are owned by institutional investors. 31.5% of Alpha Cognition shares are owned by insiders. Comparatively, 48.9% of ZIVO Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Volatility and Risk

Alpha Cognition has a beta of 2.8, meaning that its stock price is 180% more volatile than the S&P 500. Comparatively, ZIVO Bioscience has a beta of -0.06, meaning that its stock price is 106% less volatile than the S&P 500.

Valuation and Earnings

This table compares Alpha Cognition and ZIVO Bioscience”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alpha Cognition	N/A	N/A	-$13.77 million	C($0.12)	N/A
ZIVO Bioscience	$15,850.00	4,394.97	-$7.78 million	($2.58)	-7.07

ZIVO Bioscience has higher revenue and earnings than Alpha Cognition. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Alpha Cognition, indicating that it is currently the more affordable of the two stocks.

About Alpha Cognition

Alpha Cognition Inc., a clinical stage biopharmaceutical company, develops treatments for Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062 for the treatment of mild-to-moderate Alzheimer’s disease and mild traumatic brain injury; ALPHA-0602, a gene therapy for the treatment of ALS; and ALPHA-0702 and ALPHA-0802, a granulin epithelin motifs for the treatment of neurodegenerative diseases. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

About ZIVO Bioscience

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.